Indirect Costs of Respiratory Syncytial Virus Hospitalizations- A Commentary

Mar 1, 2003, 00:00
10.1046/j.1524-4733.2003.t01-1-00003.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60138-6/fulltext
Title : Indirect Costs of Respiratory Syncytial Virus Hospitalizations- A Commentary
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60138-6&doi=10.1046/j.1524-4733.2003.t01-1-00003.x
First page :
Section Title :
Open access? : No
Section Order : 13
Much controversy surrounds the choice of optimal candidates for the prophylaxis of respiratory syncytial virus (RSV) based on published cost-effective measurements. The measurement of indirect costs associated with chronic illness is increasingly being recognized as a critical portion in understanding total health-care costs. The addition of indirect cost information to current cost-effectiveness ratios can potentially alter the approval coverage for treatment by payer groups.
Categories :
  • Economic Evaluation
  • Infectious Disease
  • Respiratory-Related Disorders
  • Specific Diseases & Conditions
  • Work & Home Productivity - Indirect Costs
Tags :
Regions :
  • North America
ViH Article Tags :